Profile data is unavailable for this security.
About the company
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.
- Revenue in USD (TTM)1.00m
- Net income in USD-8.16m
- Incorporated2000
- Employees13.00
- LocationMediciNova IncSUITE 650, 4275 EXECUTIVE SQUARELA JOLLA 92037United StatesUSA
- Phone+1 (858) 373-1500
- Fax+1 (858) 404-0048
- Websitehttps://medicinova.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IO Biotech Inc | 0.00 | -88.00m | 69.17m | 68.00 | -- | 0.7185 | -- | -- | -1.44 | -1.44 | 0.00 | 1.46 | 0.00 | -- | -- | 0.00 | -76.85 | -- | -86.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.47 | -- | -- | -- |
| Vor Biopharma Inc | 0.00 | -112.46m | 69.36m | 168.00 | -- | 0.9506 | -- | -- | -1.65 | -1.65 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -66.35 | -45.79 | -72.73 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
| Quince Therapeutics Inc | 0.00 | -53.12m | 71.84m | 32.00 | -- | 1.53 | -- | -- | -1.27 | -1.27 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -47.50 | -42.72 | -50.26 | -46.06 | -- | -- | -- | -- | -- | -- | 0.2275 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
| Spero Therapeutics Inc | 118.46m | 17.46m | 71.89m | 46.00 | 4.20 | 0.8923 | 4.08 | 0.6068 | 0.3169 | 0.3169 | 2.21 | 1.49 | 0.9524 | -- | 4.11 | 2,575,196.00 | 14.03 | -35.52 | 18.79 | -41.75 | -- | -- | 14.74 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
| Medicinova Inc | 1.00m | -8.16m | 75.04m | 13.00 | -- | 1.31 | -- | 75.04 | -0.1665 | -0.1665 | 0.0204 | 1.17 | 0.0155 | -- | -- | 76,923.08 | -12.65 | -15.36 | -13.19 | -15.90 | -- | -- | -816.49 | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
| Celularity Inc | 33.52m | -154.29m | 75.19m | 120.00 | -- | 2.39 | -- | 2.24 | -8.19 | -8.19 | 1.77 | 1.43 | 0.1324 | 3.41 | 3.19 | 279,308.30 | -60.96 | -19.19 | -82.57 | -20.99 | 53.30 | -- | -460.34 | -454.79 | 0.29 | 8.56 | 0.5602 | -- | 26.68 | -- | -1,483.14 | -- | -- | -- |
| Aerovate Therapeutics Inc | 0.00 | -87.94m | 75.92m | 51.00 | -- | 0.8039 | -- | -- | -3.14 | -3.14 | 0.00 | 3.27 | 0.00 | -- | -- | 0.00 | -65.76 | -- | -74.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
| Aileron Therapeutics Inc | 0.00 | -25.22m | 77.78m | 15.00 | -- | 1.39 | -- | -- | -3.25 | -3.25 | 0.00 | 4.67 | 0.00 | -- | -- | 0.00 | -40.88 | -65.99 | -43.02 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
| ALX Oncology Holdings Inc | 0.00 | -151.16m | 77.95m | 89.00 | -- | 0.5706 | -- | -- | -2.98 | -2.98 | 0.00 | 2.59 | 0.00 | -- | -- | 0.00 | -74.50 | -34.34 | -89.35 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.0851 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| Metagenomi Inc | 55.93m | -75.00m | 78.30m | 228.00 | -- | 0.2906 | -- | 1.40 | -2.53 | -2.53 | 1.68 | 7.19 | 0.1408 | -- | 28.13 | 236,987.30 | -18.88 | -- | -22.14 | -- | -- | -- | -134.10 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -4.30m | 79.12m | 12.00 | -- | 9.63 | -- | -- | -0.3306 | -0.3306 | 0.00 | 0.6316 | 0.00 | -- | -- | 0.00 | -41.44 | -56.31 | -42.99 | -77.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 26.73 | -- | -- | -- |
| ESSA Pharma Inc | 0.00 | -27.67m | 79.46m | 50.00 | -- | 0.6163 | -- | -- | -0.6257 | -0.6257 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -19.33 | -23.01 | -19.81 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
| Boundless Bio Inc | 0.00 | -57.72m | 79.67m | 72.00 | -- | 0.4445 | -- | -- | -2.60 | -2.60 | 0.00 | 8.05 | 0.00 | -- | -- | 0.00 | -33.64 | -- | -35.41 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
| Beyondspring Inc | 1.88m | -15.57m | 79.79m | 35.00 | -- | -- | -- | 42.53 | -0.3987 | -0.3987 | 0.0481 | -0.749 | 0.0698 | -- | -- | 52,111.11 | -59.75 | -75.50 | -102.15 | -96.48 | -- | -- | -856.29 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
| Sellas Life Sciences Group Inc | 0.00 | -34.44m | 80.42m | 16.00 | -- | 24.78 | -- | -- | -0.934 | -0.934 | 0.00 | 0.0504 | 0.00 | -- | -- | 0.00 | -204.48 | -111.48 | -838.03 | -184.29 | -- | -- | -- | -1,289.42 | -- | -- | 0.00 | -- | -100.00 | -- | 9.59 | -- | -- | -- |
| Citius Pharmaceuticals Inc | 0.00 | -39.77m | 81.18m | 22.00 | -- | 0.9475 | -- | -- | -0.2443 | -0.2443 | 0.00 | 0.4741 | 0.00 | -- | -- | 0.00 | -36.91 | -30.26 | -39.00 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to MediciNova Inc's reporting currency: US Dollar USD
17.32%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| 3D Investment Partners Pte Ltd.as of 17 Apr 2024 | 5.50m | 11.22% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 685.24k | 1.40% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 607.73k | 1.24% |
| Geode Capital Management LLCas of 30 Jun 2024 | 458.77k | 0.94% |
| Citigroup Global Markets, Inc. (Investment Management)as of 30 Jun 2024 | 447.96k | 0.91% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 210.00k | 0.43% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 157.20k | 0.32% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 145.90k | 0.30% |
| Bridgeway Capital Management LLCas of 30 Jun 2024 | 145.15k | 0.30% |
| Charles Schwab Investment Management, Inc.as of 30 Jun 2024 | 134.79k | 0.28% |
More ▼
Data from 30 Jun 2024 - 10 Oct 2024Source: FactSet Research Systems Inc.
